Fortitude Advisory Group L.L.C. Sells 55 Shares of Eli Lilly and Company $LLY

Fortitude Advisory Group L.L.C. lessened its position in Eli Lilly and Company (NYSE:LLY) by 4.2% during the second quarter, Holdings Channel reports. The fund owned 1,248 shares of the company’s stock after selling 55 shares during the period. Fortitude Advisory Group L.L.C.’s holdings in Eli Lilly and Company were worth $973,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Precedent Wealth Partners LLC lifted its stake in Eli Lilly and Company by 15.3% in the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock worth $229,000 after purchasing an additional 39 shares during the last quarter. Family CFO Inc bought a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at about $54,000. Duquesne Family Office LLC grew its position in Eli Lilly and Company by 52.5% during the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock worth $78,321,000 after acquiring an additional 32,640 shares during the last quarter. Corient IA LLC purchased a new position in Eli Lilly and Company in the 1st quarter worth approximately $570,000. Finally, Emerald Advisors LLC lifted its position in Eli Lilly and Company by 60.8% in the second quarter. Emerald Advisors LLC now owns 1,021 shares of the company’s stock valued at $796,000 after purchasing an additional 386 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Gabrielle Sulzberger acquired 117 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average price of $641.18 per share, with a total value of $75,018.06. Following the transaction, the director directly owned 2,703 shares in the company, valued at approximately $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO David A. Ricks bought 1,632 shares of the company’s stock in a transaction on Tuesday, August 12th. The stock was bought at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the acquisition, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. This represents a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 4,514 shares of company stock worth $2,894,841 over the last three months. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Up 2.5%

NYSE:LLY opened at $840.46 on Monday. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The firm’s 50-day moving average price is $734.60 and its 200-day moving average price is $765.44. The company has a market capitalization of $795.46 billion, a PE ratio of 54.93, a P/E/G ratio of 1.17 and a beta of 0.47. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $937.00.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the previous year, the firm posted $3.92 earnings per share. Eli Lilly and Company’s quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Analysts Set New Price Targets

LLY has been the topic of several recent analyst reports. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Guggenheim reduced their price target on Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating on the stock in a report on Wednesday, August 13th. Deutsche Bank Aktiengesellschaft reduced their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research note on Monday, August 11th. Finally, Wall Street Zen downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 20th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $938.94.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.